GHRP-2
Also known as Pralmorelin · GH-releasing peptide 2
GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
GH Axis
This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.
Evidence visual
GHRP-2 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
high
Regulatory
not approved
WADA
S2
FDA
unknown
Route
intravenous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
GHRP-2 (pralmorelin) is a GH secretagogue that stimulates GH release. Human studies report IV doses in the 1-2 µg/kg range comparing GH/PRL/ACTH/cortisol responses in young and elderly cohorts. Also used in diagnostic GH stimulation testing in some regions. Endocrine spillover to ACTH/cortisol/prolactin is a meaningful risk.
Decision path
Where GHRP-2 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether GHRP-2 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GH secretagogue stimulating GH release; endocrine spillover to ACTH/cortisol/prolactin studied.
intravenous, subcutaneous
Human: IV 1-2 µg/kg in stimulation test protocols.
GH-axis stimulation; diagnostic use in some clinical settings.
Acute hormone response within minutes to hours in stimulation tests.
No formal label (not approved for consumer use).
Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns.
Endocrine spillover risks; avoid 'safe GH boost' framing.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Additive GH-axis stimulation plausible (mechanistic); conservative gating.
GHRH analog + GHS-R agonist: additive GH release plausible.
Multiple GHS/GHS-R stimulation; limited stacking safety evidence.
Multiple GHS/GHS-R stimulation; higher uncertainty.
Multiple ghrelin-receptor secretagogues in one stack increase endocrine noise and monitoring needs.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for GHRP-2.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.